Supplying the demand for granulocytes.
Kincade
Paul W
PW
D000818:Animals; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000502:physiology; D022782:CCAAT-Enhancer-Binding Protein-beta / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006098:Granulocytes / Q000166:cytology*; D006410:Hematopoiesis / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007239:Infections / Q000276:immunology; D007377:Interleukin-3 / Q000494:pharmacology; D051379:Mice; D039902:Multipotent Stem Cells / Q000166:cytology; D011518:Proto-Oncogene Proteins / Q000502:physiology; D051193:Toll-Like Receptors / Q000502:physiology; D015534:Trans-Activators / Q000502:physiology; D014158:Transcription, Genetic; D000099232:Proto-Oncogene Protein Spi-1
D022763:CCAAT-Enhancer-Binding Protein-alpha; D022782:CCAAT-Enhancer-Binding Protein-beta; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007377:Interleukin-3; D011518:Proto-Oncogene Proteins; D051193:Toll-Like Receptors; D015534:Trans-Activators; D000099232:Proto-Oncogene Protein Spi-1